Pages that link to "Q40821551"
Jump to navigation
Jump to search
The following pages link to Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma (Q40821551):
Displaying 50 items.
- Quality of life and emotional distress in advanced prostate cancer survivors undergoing chemotherapy (Q24796034) (← links)
- Concurrent chemoradiation for high-risk prostate cancer (Q26798912) (← links)
- A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. (Q33358093) (← links)
- Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer (Q33366110) (← links)
- Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). (Q33376623) (← links)
- Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients (Q33384212) (← links)
- Complications of advanced prostate cancer (Q33800964) (← links)
- Chemotherapy for advanced hormone refractory prostate cancer (Q33800983) (← links)
- Taxanes in hormone-refractory prostate cancer. (Q33845088) (← links)
- Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy (Q33970538) (← links)
- Chemotherapy for androgen- independent prostate cancer: myth or reality (Q34108009) (← links)
- Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress? (Q34155429) (← links)
- Paclitaxel and docetaxel in prostate cancer (Q34348284) (← links)
- Treatment options in hormone-refractory prostate cancer: current and future approaches (Q34481266) (← links)
- The treatment challenge of hormone-refractory prostate cancer (Q34504202) (← links)
- Systemic treatment and new developments in advanced prostate cancer (Q34558153) (← links)
- Highlights of contemporary issues in the medical management of prostate cancer (Q34793091) (← links)
- Hormone-refractory Prostate Cancer (Q34795762) (← links)
- Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine (Q35022089) (← links)
- Current strategies in the management of hormone refractory prostate cancer (Q35145701) (← links)
- Pharmacological factors influencing anticancer drug selection in the elderly (Q35182963) (← links)
- Is There a Standard Chemotherapeutic Regimen for Hormone-Refractory Prostate Cancer? Present and Future Approaches in the Management of the Disease (Q35579300) (← links)
- Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease (Q35640625) (← links)
- New standards in the chemotherapy of metastatic hormone-refractory prostate cancer (Q36066144) (← links)
- The current role of chemotherapy in metastatic hormone-refractory prostate cancer (Q36122672) (← links)
- Cytotoxic chemotherapy for prostate cancer: Who and when? (Q36563656) (← links)
- The future in advanced prostate cancer: take your partners or is the last dance for me? (Q36598427) (← links)
- The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer (Q37091477) (← links)
- Docetaxel for the treatment of hormone-refractory prostate cancer. (Q39345902) (← links)
- Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients (Q39365162) (← links)
- Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer (Q39413134) (← links)
- Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy. (Q40113425) (← links)
- Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer (Q40340477) (← links)
- Chemotherapy for hormone-resistant prostate cancer: Where are we today? (Q42119686) (← links)
- Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: a single-arm prospective study using a historical control for comparison (Q42140230) (← links)
- The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study (Q43658188) (← links)
- Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy (Q43704979) (← links)
- Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study (Q43781929) (← links)
- Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma (Q43937942) (← links)
- Acute estramustine-induced hypocalcemia unmasking severe vitamin D deficiency (Q44009100) (← links)
- A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. (Q44291819) (← links)
- The mechanism of action of docetaxel (Taxotere®) in xenograft models is not limited to bcl-2 phosphorylation (Q44632200) (← links)
- Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma (Q44635853) (← links)
- Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study (Q44635854) (← links)
- Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial (Q44644578) (← links)
- A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer (Q46495105) (← links)
- RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model (Q46715452) (← links)
- Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study (Q60368012) (← links)
- Pharmacology of antineoplastic agents in older cancer patients (Q73308736) (← links)
- [Current multidisciplinary treatment of metastatic prostatic cancer] (Q75308104) (← links)